Kornimate/medical-research-clean huggingface dataset:
clinical and biological sample database of chinese elderly patients with multiple diseases

Conditions: Comorbidities and Coexisting Conditions; Old Age; Debility

Summary: the investigators aim to establish a clinical database and biobank for elderly patients with multiple diseases. the collected data will include demographic information, comorbidity characteristic, frail scale, age-adjusted charlson comorbidity index, relevant blood tests, the results of imaging examination, prescription of drugs, length of hospital stay, number of overall rehospitalizations and death. with this database, the investigators intend to formulate an individualized treatment strategy for these patients.

according to the china health and aging tracking survey, a significant proportion of elderly individuals aged over 65 suffer from two or more chronic diseases, with prevalence rates ranging from 22.5% to 47.5%. however, due to the decentralized storage of health data, lack of standardization, and collaboration barriers, it is challenging to make use of this information in a meaningful way.therefore, there is an urgent need to overcome the technical challenges and build an intelligent diagnosis and treatment system for this vulnerable population. to achieve this goal, it is necessary to establish a clinical database and biobank that includes data on all elderly patients with multimorbidity. this will enable researchers to conduct clinical research on various factors, including clinical and biological predictors of adverse events such as emergency visits, strokes, heart failure, myocardial infarction, tumors, and acute chronic obstructive pulmonary disease. additionally, the database will facilitate the development of systematic and individualized evaluation tools for elderly patients with multimorbidity, identify prognostic factors that improve short- and long-term outcomes, and enable the participation in multi-center trials at the national or international level. ultimately, this effort will help establish clinical database and biobank data collection standards for future studies.

Eligibility criteria:
inclusion criteria: * (1) written and informed consent, (2) participants aged 18 years or older. exclusion criteria: * (1) unwilling to participate in the study, (2) unable or unwilling to cooperate with the baseline or follow-up data collection.

Keywords: cognition disorders frailty coronary heart disease atrial fibrillation stroke heart failure hypertension valvular heart disease
obstetric outcomes in women with pcos

Conditions: Polycystic Ovary Syndrome, PCOS

Summary: the aim of the study is to investigate body composition in newborn children of women with pcos and controls and to investigate adverse obstetric outcomes in pregnant women with pcos.

a prospective cohort study investigating 208 women with pcos giving birth after singleton pregnancies at odense univesity hospital during 2003-2011 and a date-of-childbirth matched control group of 1040 women. anthropometric data from children is recorded as well as data on maternal parity, age, pre-gestational bmi, and adverse obstetric outcomes.

Eligibility criteria:
inclusion criteria: * diagnosed with pcos and giving birth during 2003-2011 exclusion criteria: * multiple pregnancy

Keywords: pcos pregnancy obstetric
ocular blood flow in glaucoma patients - the leuven eye study

Conditions: Open Angle Glaucoma; Normal Tension Glaucoma

Summary: glaucoma is a leading cause of blindness worldwide, whose treatment - intraocular pressure lowering - is only partially effective in preventing disease progression. accordingly, other variables, such as ocular blood flow-related factors, have been implicated in disease pathogenesis. however, most findings involving vascular variables come from partial, small-scale studies. furthermore, recent technological advances have identified a number of ocular blood flow variables that have yet to be tested in large scale trials. therefore, a study that specifically aims at uncovering the role of vascular aspects in glaucoma is needed. for this purpose, a cross-sectional, observational case-control study will be conducted in the university hospitals leuven. this will be the largest-yet study on the subject, involving more than 750 patients. this will allow the creation of a specific cohort of patients where the vascular aspects are thought to be particularly important (low-tension glaucoma). it will use the largest combination yet of vascular-related measuring techniques (dynamic contour tonometry, optic coherent tomography, colour doppler imaging and retinal oximetry)

1. demographic and clinical ophthalmology-related examination data will be collected, including intraocular pressure measurement using dynamic contour tonometry 2. visual field testing will be performed. 3. structural damage will be documented by a retinal nerve fiber layer analysis (through heidelberg retinal tomograph) 4. high definition optical coherent tomograph imaging of the submacular and peripapillary choroidal thickness will be performed. 5. color doppler imaging of the retrobulbar vessels will be performed, with analysis of the doppler waveform (peak systolic, end diastolic velocities and resistivity index) 6. retinal oximetry will be performed with the analysis of the arterial and venous saturations of retinal vessels

Eligibility criteria:
inclusion criteria: * individuals over 18 years old * willing to sign an informed consent and able to comply with the requirements of the study * having no other ocular diseases besides glaucoma exclusion criteria: * history of ocular trauma * intraocular surgery (except for cataract surgery) * eye disease (except glaucoma) * systemic diseases with ocular involvement like diabetes
thyroid hormone for thyroid cancer

Conditions: Differentiated Thyroid Cancer; Thyroid Cancer; Levothyroxine; Liothyronine; Thyroid Hormones

Summary: this study will be a multicentre prospective cohort study on th-substitution with liothyronine (l-t3) and levothyroxine (l-t4) in dtc patients after th-withdrawal. the first cohort is patients treated in the university medical centre groningen (umcg) with l-t3 according to standard local protocol. the second cohort is patients treated in the radboud university medical centre (radboud umc) with l-t4, also according to standard local protocol. we will compare effects of l-t3 or l-t4 on tsh, thyroglobulin (tg), quality of life (qol), weight and cardiovascular parameters.

while treatment with l-t4 after th-withdrawal is widely used in dtc patients to suppress tsh and improve hypothyroid symptoms, the value of l-t3 has not been evaluated in this context. lifelong monotherapy with l-t3 should not be preferred over l-t4 yet, short-term use of l-t3 to initiate th-supplementation can be safely implemented. we hypothesize that initial treatment with l-t3 can have a more rapid effect on tsh-levels and earlier relieve of hypothyroid symptoms resulting in a better qol. to evaluate th-supplementation with l-t3, we will conduct a prospective cohort study comparing the initiation of th-supplementation after th-withdrawal in two cohorts of dtc patients: patients treated in the university medical centre groningen (umcg) receiving l-t3 and patients treated in the radboud university medical centre (radboud umc) receiving l-t4. we will compare potency to suppress tsh, effect on qol and effects on thyroid- and cardiovascular parameters. patients (18-75 years) diagnosed with high-risk dtc treated in the umcg or radboud umc and receiving thst with l-t3 or l-t4 after th-withdrawal will be eligible for inclusion. the primary objective is to compare the proportion of patients reaching target tsh-levels after two weeks of substitution with l-t3 or l-t4. secondary objectives are to compare the effects of l-t3 and l-t4 in the first 6 months of treatment on serum thyroid parameters tsh and tg, quality of life, weight, and cardiovascular parameters

Eligibility criteria:
inclusion criteria: * histologically confirmed dtc (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma) * classified as high-risk dtc according to the ata guidelines (1) or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician). * prepared for rai-therapy with th-withdrawal * patients have to be fit to adhere to the study protocol * patients have to be able to read and understand the dutch language exclusion criteria: * pregnancy * patients with a psychiatric history or history of depression * patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that l-t3 is unsuitable. conditions or drugs interfering with thyroid hormone uptake: - patients with a history of atrophic gastriti
effect of the foot care protocol applied to elderly people

Conditions: Foot

Summary: the study was carried out randomized-controlled experimental research to determine the foot health status and factors affecting it among elderly individuals, to develop a protective and developmental protocol for foot health of elderly individuals and to determine the effect of this protocol on foot health problems, foot care knowledge levels and foot care behaviors.

data for the foot health status and factors affecting it among elderly individuals were collected from 28 april 2017 to 5 february 2018. the population of the study comprised 132 elderly individuals living in nursing home linked to the ministry of family and social policies in ordu central county. in the research, 118 individuals in the nursing home were reached, the research began with 65 elderly individuals abiding by the inclusion criteria randomized into experimental and control groups and was completed with 57 individuals (experiment: 28, control: 29). data were collected using the standardized mini mental test, elderly descriptive form, foot examination form, foot care knowledge level form, foot care behavior scale, falling form.. ethics committee permission, organization permission and written informed consent from individuals were obtained. five interviews were performed with elderly individuals in the experimental group, while only two interviews were held with elderly individuals in the control group to apply the data collection tools.

Eligibility criteria:
inclusion criteria: living in nursing home during the research process, not dependent on bed, self-sufficient, no communication problem, elderly people have good cognitive functions ,(according to the revised mini mental test) elderly people with any foot problem (dermatological, orthopaedic, circulation, sensory problems, problems related to the feet, self-care problems), exclusion criteria: elderly people who are diagnosed with diabetes mellitus

Keywords: foot disease foot care protocol nursing care
study to compare different formulations of azd3355

Conditions: Gastroesophageal Reflux Disease

Summary: the purpose of the study is to compare different formulations of azd3355 in regard to possible adverse events such as sensations of numbness, tinglings and heat in the skin.


Eligibility criteria:
inclusion criteria: * provision of written informed consent * female subjects with no childbearing potentials or using highly efficient contraceptive methods * clinically normal physical findings exclusion criteria: * clinically significant illness within 2 weeks prior to the first dose of investigational product * history of clinically significant disease * use of prescribed medication during the 2 weeks before administration of the first dose of investigational product

Keywords: reflux inhibitor gerd formulations
effectiveness of prism spectacles in patients with age related macular degeneration

Conditions: Age-Related Macular Degeneration

Summary: a study is conducted to determine the effectiveness of prism spectacles in improving visual acuity with age related macular degeneration patients and to assess the improvement in quality of life in patients by using prism spectacles.

a random sampling technique will be used to allocate patient in interventional and non-interventional group. the diagnosed patients of age-related macular degeneration are assessed for prism spectacles for near vision and prism glasses will be dispensed to the patients. each subject will be interviewed to fill the proforma after taking the informed consent. the results of this study will show the effectiveness of prism glasses in patients with age related macular degeneration in their daily routine near work as compared to conventional glasses.

Eligibility criteria:
inclusion criteria: * patients having age \>50 years with age related macular degeneration. * patients of both genders (male and female). * participants who will be willing to give informed consent for participation in the study. exclusion criteria: * presence of all ocular disease and systemic ocular pathologies able to impair visual function. * presence of disorders causing choroidal neovascularization other than age related macular degeneration. * patients with mental illness, dementia, and severe physical limitations
evaluation of the effectiveness of extracorporeal shockwave therapy in patients with patellar tendinopathy on its micromorphology

Conditions: Patellar Tendinopathy

Summary: this work is designed as a prospective cohort study, in which the effects of low-energy focused extracorporeal shock wave therapy (eswt) in patients with patellar tendinopathy (pt) will be monitored on its micromorphology. it is estimated that at least 21 patients will participate. in addition, there will be a small control group of healthy tendons which will be monitored to observe magnitude of natural changes.

this work is designed as a prospective cohort study, in which the effects of low-energy focused extracorporeal shock wave therapy (eswt) in patients with patellar tendinopathy (pt) will be monitored on its micromorphology. it is estimated that at least 21 patients will participate. in addition, there will be a small control group of healthy tendons which will be monitored to observe magnitude of natural changes. the research within one patient will last a total of 16 weeks from the initial to the final examination. potential participants will be selected based on the recommendation of a specialist doctor and their suitability will be assessed according to the inclusion criteria. they will then be invited to an initial examination. this will include an objective examination by a physiotherapist, a subjective assessment by the patient and an ultrasonographic (usg) examination followed by a micromorphological analysis using special software.

Eligibility criteria:
inclusion criteria: * patient is a recreational athlete performing intensive sport activity loading patellar tendon (running, jumping, strength training etc.) at least 3 days in a week for minimum of 1 hour per session, * is in age between 18-40 years, * has a patellar tendon pain, which limits (at least in part) the quality of normal daily or sports activities, * has clinical manifestation of patellar tendinopathy (pain and impaired function) confirmed by clinician, * has symptoms only in one leg, the other one is asymptomatic. exclusion criteria: * any contraindication for eswt is present (according to international society for medical shockwave treatment (ismst) consensus at https://shockwavetherapy.org), * patient is aware of any symptomatic mechanical tendon damage in the past (e.g., partial or complete rupture in relation to the injury), * neurological, oncological, or systemic disease (e.g., neuropathy, lupus or rheumatic arthritis) coexists, * is/was already treated for pt elsewhere (e.g., platelet-rich plasma therapy, physiotherapy) * is using blood thinning medications or statins.

Keywords: patellar tendinopathy extracorporeal shock wave therapy ultrasonography
feasibility in identification of breast cancer candidates for elimination of axillary surgery

Conditions: Breast Cancer

Summary: preoperative identification of patients with pathologic complete response or residual disease in axilla can aid in tailoring subsequent axillary surgery including omission of axillary surgery based on tumor biology and response to neoadjuvant chemotherapy.

objective: to determine the accuracy of on-treatment core needle biopsy in breast to predict nodal response after neoadjuvant chemotherapy. outline: early breast cancer patients aged above 18 and below 70 years with biopsy-confirmed, clinically t1-4, n1-3, and m0 disease are eligible for this study. breast cancer is proven pathologically in all patients using the baseline core needle biopsy, and the skin of all patients is tattooed at the baseline. metastatic lymph nodes are diagnosed with core needle biopsy or fine needle aspiration. all the patients undergo clip placement into node with biopsy-confirmed metastases at the time of diagnosis. for patients who were not evaluated as progressive disease by the latest imaging measurement, repeated cnb (rcnb) was performed after 2-4 cycles of nac, depending on the total cycles of nac., repeated core needle biopsy is conducted within the baseline tattooed area after 2 to 4 cycles of neoadjuvant chemotherapy, depending on the total cycles of chemotherapy. tissue is acquired from different sections of the lesion from different angles to minimize the impact of tumor heterogeneity. for each patient, 3 to 4 tissue specimens are collected and sent for pathological review to examine whether there is residual malignancy (residual cancer, pleomorphic tissue) in the tumor site that is tattooed. all the patients receive planned axillary surgery after completion of neoadjuvant chemotherapy. the surgical approach was determined by the treating breast surgical oncologist including targeted axillary dissection (tad) or axillary lymph node dissection, mainly based on the intraoperative tad results projected accrual: a total of 180 patients will be accrued for this study within 5 years.

Eligibility criteria:
inclusion criteria: 1. clinical stage t1-4 n1-3m0 breast cancer at diagnosis (prior to neoadjuvant chemotherapy) by american joint committee on cancer (ajcc) staging 7th edition 2. aged above 18 and below 70 years 3. no other malignancy within 5 years of registration with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix 4. patients must have had estrogen receptor, progesterone receptor and her2 status (by immunohistochemistry \[ihc\] and/or in situ hybridization \[ish\]) evaluated on core needle biopsy prior to starting neoadjuvant chemotherapy 5. completing all planned cycles and regimens of neoadjuvant chemotherapy followed by axillary surgery exclusion criteria: 1. nonrepresentative core needle biopsy in the breast during neoadjuvant chemotherapy 2. inflammatory breast cancer

Keywords: neoadjuvant chemotherapy nodal response core needle biopsy
surgical treatment of hypertrophic obstructive cardiomyopathy with severe mitral insufficiency.

Conditions: Hypertrophic Obstructive Cardiomyopathy

Summary: compare the results of reconstruction and mitral valve replacement in the surgical treatment of obstructive hypertrophic cardiomyopathy with severe mitral insufficiency.

many years myoectomy for morrow was the gold standard in the treatment of obstructive hypertrophic cardiomyopathy. currently more retrospective data in the literature about the good results the extended septal myectomy. but the question remains what is best for patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency: use extended myoectomy with mitral valve repair a or replacement.

Eligibility criteria:
inclusion criteria: * able to sign informed consent and release of medical information forms * age ≥ 18 years * obstructive hypertrophic cardiomyopathy * surgically significant mitral insufficiency * ii-iv (nyha), * average systolic pressure gradient greater than 50 mm hg. art. at rest; * basal or medium ventricular obstruction exclusion criteria: * related defect of the aortic valve; * organic mitral valve disease (dysplasia, rheumatic fever, infective endocarditis); * surgically significant coronary artery lesions; * patients requiring implantation of a cardioverter-defibrillator

Keywords: hypertrophic cardiomyopathy mitral valve
postpartum anxiety, breastfeeding and infant health among taiwanese women

Conditions: Postpartum Anxiety; Breastfeeding; Infant Conditions

Summary: this is a prospective, longitudinal and observational study designed to investigate the trajectories of postpartum anxiety and its determinants in the first year after childbirth. this study also examine the associations between postpartum anxiety and infant health outcome, including breastfeeding patterns, excessive crying and body weight growth. primipara aged 20-49 with term baby will be invited. demographics, maternal-newborn characteristics, and anxiety symptoms will be collected during the first week postpartum (t1). questionnaires will be follow-up by mail and telephone reminder in 1 (t2), 3 (t3), 6 (t4) and 12 months (t5) postpartum. the primary outcome is postpartum anxiety using the spielberger's state-trait anxiety inventory (stai); the secondary outcomes are infant health outcomes including breastfeeding patterns, excessive crying and body weight growth. a linear mixed model (lmm) is used to determine the trajectories of postpartum anxiety over time and to examine whether specific demographic and maternal characteristics predict the trajectories of postpartum anxiety. the key findings may contribute to promote early identification and secondary preventive interventions for women with postpartum anxiety.

ditto

Eligibility criteria:
inclusion criteria: * 20-49 years old * primipara exclusion criteria: * preterm birth * infants with severe congenital malformations/medical conditions or fetal/neonatal death * current use of antidepressant or antipsychotics * thoughts of self-harm or suicide
subcutaneously administered aldesleukin ( interleukin-2; il-2 ) therapy in hiv-infected patients

Conditions: HIV Infections

Summary: to compare the effects of low-dose versus high-dose subcutaneous ( sc ) aldesleukin ( interleukin-2; il-2 ) on immunologic and virologic markers in hiv-infected patients. to compare the effects of monthly versus bimonthly administration of sc il-2 on these markers. interleukin-2 is a protein that is naturally produced by lymphocytes. in an initial study, patients in an earlier stage of hiv-1 infection tended to tolerate sc il-2 better than those with more advanced infections, and those with higher baseline cd4+ counts tended to derive the greatest benefit.

interleukin-2 is a protein that is naturally produced by lymphocytes. in an initial study, patients in an earlier stage of hiv-1 infection tended to tolerate sc il-2 better than those with more advanced infections, and those with higher baseline cd4+ counts tended to derive the greatest benefit. patients are randomized to one of four treatment arms; patients receive either low-dose or high-dose sc il-2 for 5 days either on a monthly or bimonthly schedule for approximately 6 months.

Eligibility criteria:
inclusion criteria patients must have: * hiv positivity. * cd4 count \>= 500 cells/mm3. * no history of aids-defining opportunistic infection, or malignancy other than mucocutaneous kaposi's sarcoma. concurrent medication: required: * concurrent fda-approved antiretroviral therapy (azt, ddi, ddc, d4t). prior medication: required: * fda-approved antiretroviral therapy for at least 6 weeks prior to study entry. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * significant cardiac, pulmonary, thyroid, renal, or cns disease. prior medication: excluded: * prior il-2. * systemic corticosteroids, chemotherapy, or experimental therapy within 4 weeks prior to study entry.

Keywords: interleukin-2 aids-related complex